Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Biliary Tract Diseases

Free Subscription Articles published in Hepatology Retrieve available abstracts of 110 articles: HTML format

Single Articles

May 2025
1. O'ROURKE CJ, Andersen JB
   Intrahepatic Cholangiocarcinoma PANoptosidy.
   Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001398.
   PubMed    
   
   
   April 2025
2. LEE MH
   Reply: Oversights in Stratification and Viral Screening- A Critical Appraisal of a MetS-Cholangiocarcinoma Cohort.
   Hepatology. 2025 Apr 29. doi: 10.1097/HEP.0000000000001370.
   PubMed    
   
   
   
3. HUANG J
   Letter to the editor: Oversights in stratification and viral screening- A critical appraisal of a MetS-cholangiocarcinoma cohort.
   Hepatology. 2025 Apr 29. doi: 10.1097/HEP.0000000000001369.
   PubMed    
   
   
   
4. HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al
   Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
   Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351.
   PubMed     Abstract available
   
   
   
5. YU Y, You Y, Duan Y, Kang M, et al
   Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma.
   Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001352.
   PubMed     Abstract available
   
   
   
6. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
   Reply: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
   Hepatology. 2025 Apr 11. doi: 10.1097/HEP.0000000000001326.
   PubMed    
   
   
   
7. YANG LX, Gao Q, Shi JY, Wang ZC, et al
   Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
   Hepatology. 2025 Apr 7. doi: 10.1097/HEP.0000000000001274.
   PubMed    
   
   
   
8. SAMPLE JW
   A Niche Discovery: Spatial Mapping of Therapeutic Targets in Biliary Atresia.
   Hepatology. 2025;81:1109-1110.
   PubMed    
   
   
   
9. MOL B, Werner E, Culver EL, van der Meer AJ, et al
   Epidemiological and economical burden of cholestatic liver disease.
   Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001341.
   PubMed     Abstract available
   
   
   March 2025
10. GRONBAEK L, Vilstrup H, Jepsen P
    Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001325.
    PubMed    
    
    
    
11. LEVY C, Bowlus CL
    Erratum: Primary biliary cholangitis: Personalizing second-line therapies.
    Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001275.
    PubMed    
    
    
    
12. MACIAS RIR, Roessler S, Verstegen MMA
    Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001322.
    PubMed    
    
    
    
13. CHEN TI, Chen MH, Yin SC, Lin CJ, et al
    Associations between metabolic syndrome and cholangiocarcinoma risk: A large-scale population-based cohort study.
    Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001312.
    PubMed     Abstract available
    
    
    
14. SINGH Y, Eaton JE, Venkatesh SK, Welle CL, et al
    Deep learning analysis of magnetic resonance imaging accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001314.
    PubMed     Abstract available
    
    
    
15. GORES GJ, Malhi H
    The dynamic landscape of cholestatic liver disease.
    Hepatology. 2025 Mar 7. doi: 10.1097/HEP.0000000000001298.
    PubMed    
    
    
    February 2025
16. HONG L, Mei J, Sun X, Wu Y, et al
    Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001283.
    PubMed     Abstract available
    
    
    
17. CANCADO GGL, Deeb M, Gulamhusein AF
    Liver transplantation for cholestatic liver diseases: Timing & disease recurrence.
    Hepatology. 2025 Feb 17. doi: 10.1097/HEP.0000000000001268.
    PubMed     Abstract available
    
    
    
18. OLAIZOLA P, Olaizola I, Fernandez de Ara M, Lapitz A, et al
    Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk.
    Hepatology. 2025 Feb 11. doi: 10.1097/HEP.0000000000001259.
    PubMed     Abstract available
    
    
    
19. YU M, Sample JW, Yan IK, Takaichi S, et al
    Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models.
    Hepatology. 2025 Feb 10. doi: 10.1097/HEP.0000000000001256.
    PubMed     Abstract available
    
    
    
20. LI B
    BileMet: A new frontier in distinguishing malignant from benign biliary conditions.
    Hepatology. 2025;81:383-384.
    PubMed    
    
    
    January 2025
21. LI B, Ilyas SI
    Unveiling the immune landscape of IDH1-mutant cholangiocarcinoma: Pathways to new therapies.
    Hepatology. 2025 Jan 21. doi: 10.1097/HEP.0000000000001241.
    PubMed    
    
    
    
22. RONCA V, Davies SP, Oo YH, Lleo A, et al
    The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.
    Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001225.
    PubMed     Abstract available
    
    
    
23. IDALSOAGA F, Arab JP
    Unraveling bile acid dynamics in severe obesity.
    Hepatology. 2025;81:1-2.
    PubMed    
    
    
    December 2024
24. BITTERMANN T, Schaubel DE
    Obeticholic acid as second-line therapy for primary biliary cholangitis: Does target trial emulation solve the issue?
    Hepatology. 2024 Dec 20. doi: 10.1097/HEP.0000000000001198.
    PubMed    
    
    
    
25. THI VU Q, Nishimura Y, Harada K, Ito H, et al
    International trends in biliary tract cancer-related mortality, 2000-2022: An observational study of the World Health Organization mortality database.
    Hepatology. 2024 Dec 19. doi: 10.1097/HEP.0000000000001200.
    PubMed     Abstract available
    
    
    
26. LUO Y, Fraser L, Jezykowski J, Gupta NA, et al
    Interleukin 8-CXCR2 mediated neutrophil extracellular trap (NET) formation in biliary atresia associated with NET-Induced stellate cell activation.
    Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001195.
    PubMed     Abstract available
    
    
    
27. CONDE DE LA ROSA L, Fabrega L, Torres S, Nunez S, et al
    Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.
    Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001184.
    PubMed     Abstract available
    
    
    
28. ZABRANSKY DJ, Kartalia E, Lee JW, Leatherman JM, et al
    Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma.
    Hepatology. 2024 Dec 3. doi: 10.1097/HEP.0000000000001185.
    PubMed     Abstract available
    
    
    
29. BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al
    Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
    Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174.
    PubMed     Abstract available
    
    
    November 2024
30. KARLSEN TH, Kaasen Jorgensen K, Bergquist A
    Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
    Hepatology. 2024 Nov 22. doi: 10.1097/HEP.0000000000001172.
    PubMed     Abstract available
    
    
    
31. LEVY C, Bowlus CL
    Primary Biliary Cholangitis: personalizing second-line therapies.
    Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001166.
    PubMed     Abstract available
    
    
    October 2024
32. FAN G, Tao C, Li L, Xie T, et al
    The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma.
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001138.
    PubMed     Abstract available
    
    
    
33. SCHNEIDER KM, Kummen M, Trivedi PJ, Hov JR, et al
    Role of microbiome in autoimmune liver diseases.
    Hepatology. 2024;80:965-987.
    PubMed     Abstract available
    
    
    September 2024
34. JALAN-SAKRIKAR N, Guicciardi ME, O'Hara SP, Azad A, et al
    Central role for cholangiocyte pathobiology in cholestatic liver diseases.
    Hepatology. 2024 Sep 9. doi: 10.1097/HEP.0000000000001093.
    PubMed     Abstract available
    
    
    
35. CORNILLET M, Geanon D, Bergquist A, Bjorkstrom NK, et al
    Immunobiology of primary sclerosing cholangitis.
    Hepatology. 2024 Sep 2. doi: 10.1097/HEP.0000000000001080.
    PubMed     Abstract available
    
    
    August 2024
36. PANT K, Richard S, Peixoto E, Baral S, et al
    Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling.
    Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001055.
    PubMed     Abstract available
    
    
    
37. XIAO MH, Ma D, Wu S, Huang Z, et al
    Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia.
    Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001064.
    PubMed     Abstract available
    
    
    
38. BJORNSSON ES, Devarbhavi HC
    Drug induced cholestatic liver diseases.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001052.
    PubMed     Abstract available
    
    
    
39. BANALES JM, Lapitz A, Fabris L
    Comparative performance of methylation DNA markers, brushing cytology, and FISH in diagnosing malignant biliary strictures.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001050.
    PubMed    
    
    
    July 2024
40. ZHANG X, Liu H, Cai P, Huang Z, et al
    Mdka produced by the activated HSCs drives bipotential progenitor cell redifferentiation during zebrafish biliary-mediated liver regeneration.
    Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001031.
    PubMed     Abstract available
    
    
    
41. SUTTON H, Sokol RJ, Kamath BM
    IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon?
    Hepatology. 2024 Jul 25. doi: 10.1097/HEP.0000000000001032.
    PubMed    
    
    
    
42. ZHUANG Y, Ortega-Ribera M, Szabo G
    Reply to: Exercise greater caution in bile acid research.
    Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001017.
    PubMed    
    
    
    
43. YI C, Chen L, Tao B, Wang X, et al
    Letter to the Editor: Exercise greater caution in bile acid research.
    Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001013.
    PubMed    
    
    
    
44. ZHANG L, Xie P, Li M, Zhang X, et al
    Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
    Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
    PubMed     Abstract available
    
    
    June 2024
45. ZHU M, Qu M, Lv S, Pan F, et al
    Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study.
    Hepatology. 2024 Jun 24. doi: 10.1097/HEP.0000000000000932.
    PubMed    
    
    
    
46. COOLEY MA, Schneider AR, Barr Fritcher EG, Milosevic D, et al
    Utility of methylated DNA markers for the diagnosis of malignant biliary strictures.
    Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000970.
    PubMed     Abstract available
    
    
    
47. OH DY, Ikeda M, Lee CK, Rojas C, et al
    Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.
    Hepatology. 2024 Jun 14. doi: 10.1097/HEP.0000000000000965.
    PubMed     Abstract available
    
    
    
48. YANG S, Fu J, Qin W, Wang R, et al
    Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases.
    Hepatology. 2024 Jun 11. doi: 10.1097/HEP.0000000000000957.
    PubMed     Abstract available
    
    
    
49. HUANG YH, Loftfield E, Argirion I, Adami HO, et al
    Association of tea and coffee consumption and biliary tract cancer risk: The Biliary Tract Cancers Pooling Project.
    Hepatology. 2024;79:1324-1336.
    PubMed     Abstract available
    
    
    
50. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
    Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
    Hepatology. 2024;79:1279-1292.
    PubMed     Abstract available
    
    
    May 2024
51. AYDIN O, Wahlstrom A, de Jonge PA, Meijnikman AS, et al
    An integrated analysis of bile acid metabolism in humans with severe obesity.
    Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000938.
    PubMed     Abstract available
    
    
    
52. KELLERMAYER R, Carbone M, Horvath TD, Szigeti RG, et al
    Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune mediated liver injury.
    Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000926.
    PubMed     Abstract available
    
    
    April 2024
53. HITOMI Y, Ueno K, Aiba Y, Nishida N, et al
    A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894.
    PubMed     Abstract available
    
    
    March 2024
54. JONES DE, Beuers U, Bonder A, Carbone M, et al
    Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
    Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
    PubMed     Abstract available
    
    
    
55. LAL BB, Alam S, Sibal A, Kumar K, et al
    Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
    PubMed     Abstract available
    
    
    
56. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
    Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
    PubMed     Abstract available
    
    
    
57. PANDURANGI S, Mourya R, Nalluri S, Fei L, et al
    Diagnostic accuracy of serum matrix metalloproteinase-7 as a biomarker of biliary atresia in a large North American cohort.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000827.
    PubMed     Abstract available
    
    
    
58. ZHUANG Y, Szabo G
    Reply to: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? more need to be known.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000816.
    PubMed    
    
    
    
59. KELLERER M, Javed S, Casar C, Will N, et al
    Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000830.
    PubMed     Abstract available
    
    
    
60. JIANG L, Yang Z
    Letter to the Editor: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? ---more need to be known.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000813.
    PubMed    
    
    
    
61. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
    Autoimmune diseases in primary sclerosing cholangitis and their first-degree relatives.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000823.
    PubMed     Abstract available
    
    
    February 2024
62. ZHANG H, Zhu K, Zhang R, Guo Y, et al
    Oleic acid-PPARgamma-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000784.
    PubMed     Abstract available
    
    
    January 2024
63. WILBUR HC, Soares HP, Azad NS
    Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000760.
    PubMed     Abstract available
    
    
    
64. BARGELLINI I, Rimassa L, Masi G
    SIRT and chemotherapy in unresectable iCCA: Ready to take off.
    Hepatology. 2024;79:9-11.
    PubMed    
    
    
    
65. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
    Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
    Hepatology. 2024;79:39-48.
    PubMed     Abstract available
    
    
    December 2023
66. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    PubMed    
    
    
    
67. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    PubMed    
    
    
    
68. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
    Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
    Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
    PubMed     Abstract available
    
    
    November 2023
69. GHOSH S, Devereaux MW, Liu C, Sokol RJ, et al
    LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents parenteral nutrition associated cholestasis in mice.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000690.
    PubMed     Abstract available
    
    
    
70. GEHL V, O'Rourke CJ, Andersen JB
    Immunogenomics of cholangiocarcinoma.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000688.
    PubMed     Abstract available
    
    
    
71. HE S, Peng Y, Wei Q
    Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
    PubMed    
    
    
    
72. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
    Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
    PubMed    
    
    
    
73. LIU ZP, Sun XH, Yu C, Yin XY, et al
    Letter to the Editor: How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma?
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000651.
    PubMed    
    
    
    
74. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
    ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
    Hepatology. 2023;78:1337-1351.
    PubMed     Abstract available
    
    
    
75. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
    Metabolic reprogramming and its clinical implication for liver cancer.
    Hepatology. 2023;78:1602-1624.
    PubMed     Abstract available
    
    
    October 2023
76. RATTI F, Marino R, Groot Koerkamp B, Aldrighetti L, et al
    Reply: "How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma".
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000659.
    PubMed    
    
    
    
77. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    PubMed     Abstract available
    
    
    
78. HU YF, Ma WJ, Jin YW, Li FY, et al
    Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000634.
    PubMed    
    
    
    
79. 
    Erratum: Modulation of the tryptophan hydroxylase 1/monoamine oxidase-A/5-hydroxytryptamine/5-hydroxytryptamine receptor 2A/2B/2C axis regulates biliary proliferation and liver fibrosis during cholestasis.
    Hepatology. 2023;78:E86.
    PubMed    
    
    
    September 2023
80. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
    Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
    PubMed     Abstract available
    
    
    
81. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
    Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
    PubMed     Abstract available
    
    
    
82. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
    Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
    PubMed     Abstract available
    
    
    August 2023
83. PEISELER M, Tacke F
    Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
    PubMed    
    
    
    
84. RATTI F, Marino R, Olthof PB, Pratschke J, et al
    Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
    Hepatology. 2023 Aug 3. doi: 10.1097/HEP.0000000000000554.
    PubMed     Abstract available
    
    
    
85. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
    Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
    PubMed     Abstract available
    
    
    
86. BOWLUS CL, Levy C
    Optimizing treatment of primary biliary cholangitis: Is good, good enough?
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
    PubMed    
    
    
    July 2023
87. ZHAO L, Liu J, Li K, Zhang C, et al
    PTPN9 dephosphorylates FGFR2pY656/657 via interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
    Hepatology. 2023 Jul 27. doi: 10.1097/HEP.0000000000000552.
    PubMed     Abstract available
    
    
    
88. LI Y, Li B, Xiao X, Qian Q, et al
    Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
    Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
    PubMed     Abstract available
    
    
    
89. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
    Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
    PubMed     Abstract available
    
    
    
90. 
    Retraction: Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000484.
    PubMed    
    
    
    
91. JEONG H, Yoo C
    Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial - author's reply.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000535.
    PubMed    
    
    
    
92. HU YF, Gu HF, Jin YW, Li FY, et al
    Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000532.
    PubMed    
    
    
    June 2023
93. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
    Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
    PubMed     Abstract available
    
    
    
94. EKSER B, Sucu S, Mihaylov P, Emamaullee JA, et al
    Letter to the Editor mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation: Are there other challenges?
    Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000503.
    PubMed    
    
    
    May 2023
95. NEJAK-BOWEN K, Monga SP
    Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
    PubMed     Abstract available
    
    
    
96. 
    Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
    PubMed    
    
    
    
97. SHU L, Li X, Liu Z, Li K, et al
    Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
    Hepatology. 2023 May 5. doi: 10.1097/HEP.0000000000000437.
    PubMed     Abstract available
    
    
    
98. JEONG H, Kim KP, Jeong JH, Hwang DW, et al
    Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
    Hepatology. 2023;77:1540-1549.
    PubMed     Abstract available
    
    
    
99. FORMAN LM, Sapisochin G, Assis DN, Arrive L, et al
    Reply: Living donor liver transplantation for people with PSC.
    Hepatology. 2023;77:E97-E98.
    PubMed    
    
    
    April 2023
100. MACKOWIAK B, Gao B
     Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction.
     Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000416.
     PubMed    
     
     
     
101. RUSSI AE, Shivakumar P, Luo Z, Bezerra J, et al
     Plasticity between ILC2 subsets and amphiregulin expression regulate epithelial repair in biliary atresia.
     Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000418.
     PubMed     Abstract available
     
     
     
102. DANIEL N, Genua F, Jenab M, Mayen AL, et al
     The role of the gut microbiome in the development of hepatobiliary cancers.
     Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
     PubMed     Abstract available
     
     
     
103. HARTL L, Reiberger T, Trauner M
     Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
     Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
     PubMed    
     
     
     
104. UMAR S, Nadeem A, Nadeem M
     Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
     Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
     PubMed    
     
     
     
105. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
     Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
     Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
     PubMed     Abstract available
     
     
     
106. YOO C, Javle MM, Verdaguer Mata H, de Braud F, et al
     Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
     Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000365.
     PubMed     Abstract available
     
     
     
107. CABALLERO-CAMINO FJ, Rodrigues PM, Wangsell F, Agirre-Lizaso A, et al
     A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans.
     Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000376.
     PubMed     Abstract available
     
     
     
108. SINGH SP, Mondia N
     Letter to the Editor: Much more needed in natural history of Alagille syndrome.
     Hepatology. 2023;77:E78.
     PubMed    
     
     
     January 2023
109. CANTALLOPS VILA P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, et al
     Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in cholangiocarcinoma.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000206.
     PubMed     Abstract available
     
     
     
110. HEINEMANN M, Adam R, Karam V, Schramm C, et al
     Letter to the Editor: Living donor liver transplantation for people with PSC.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000208.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge.